Three Seasons Wealth LLC Acquires 20,504 Shares of Pacira BioSciences, Inc. $PCRX

Three Seasons Wealth LLC increased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 87.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,835 shares of the company’s stock after acquiring an additional 20,504 shares during the period. Three Seasons Wealth LLC owned about 0.11% of Pacira BioSciences worth $991,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PCRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock worth $677,000 after purchasing an additional 1,165 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Pacira BioSciences by 49.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares during the period. Strs Ohio acquired a new position in shares of Pacira BioSciences in the 1st quarter worth approximately $75,000. Marshall Wace LLP acquired a new position in shares of Pacira BioSciences in the 2nd quarter worth approximately $4,550,000. Finally, Sei Investments Co. lifted its position in shares of Pacira BioSciences by 35.3% during the 2nd quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock worth $606,000 after buying an additional 6,609 shares during the period. Institutional investors own 99.73% of the company’s stock.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, CFO Shawn Cross sold 12,941 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total transaction of $325,595.56. Following the completion of the sale, the chief financial officer owned 105,341 shares in the company, valued at approximately $2,650,379.56. The trade was a 10.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total value of $143,702.50. Following the completion of the transaction, the senior vice president directly owned 62,284 shares in the company, valued at approximately $1,463,674. This trade represents a 8.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 31,115 shares of company stock worth $771,896 in the last ninety days. 6.40% of the stock is currently owned by insiders.

Pacira BioSciences Price Performance

PCRX opened at $25.33 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35. The stock has a market capitalization of $996.74 million, a P/E ratio of 211.10 and a beta of 0.27. The company’s 50 day simple moving average is $23.73 and its 200-day simple moving average is $23.18. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $177.38 million during the quarter, compared to the consensus estimate of $171.80 million. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.65 EPS. Sell-side analysts anticipate that Pacira BioSciences, Inc. will post 1.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PCRX has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, May 20th. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada boosted their target price on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a report on Friday, May 1st. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Finally, Needham & Company LLC raised their price target on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $29.40.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.